Prompt transfer to sulfonylureas, enabling optimal glycaemic control soon after diabetes diagnosis, may reduce the risk of future complications in those with HNF1A/HNF4A-MODY, as seen with type 1 and type 2 diabetes [26, 27]. This evidence concerns the gene HNF1A and diabetes mellitus.